Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 8, 2014, Pages 1649-1659

  Malarvizhi, Giridharan Loghanathan ^a   Retnakumari, Archana Payickattu ^a   Nair, Shantikumar ^a   Koyakutty, Manzoor ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Core shell nanomedicine; Doxorubicin; Hepatocellular carcinoma; Poly(vinyl alcohol); Sorafenib; Transferrin

Indexed keywords

CELL PROLIFERATION; CELL SIGNALING; CELLS; CONTROLLED DRUG DELIVERY; CORE SHELL NANOPARTICLES; CYTOLOGY; DISEASES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POLYVINYL ALCOHOLS; SHELLS (STRUCTURES);

CORE SHELL; DOXORUBICIN; HEPATOCELLULAR CARCINOMA; SORAFENIB; TRANSFERRIN;

TARGETED DRUG DELIVERY;

ALBUMIN; DOXORUBICIN; NANOCAPSULE; NANOPARTICLE; POLYVINYL ALCOHOL; SORAFENIB; TRANSFERRIN; CARBANILAMIDE DERIVATIVE; DRUG CARRIER; NICOTINAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG RELEASE; DRUG TARGETING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOMEDICINE; TUMOR SPHEROID; ANALOGS AND DERIVATIVES; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DRUG EFFECTS; LIVER NEOPLASMS; PROCEDURES;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NANOMEDICINE; NIACINAMIDE; PHENYLUREA COMPOUNDS; TRANSFERRIN;

EID: 84908599667     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.05.011     Document Type: Article

References (46)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
3. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
4. Malagari K., Chatzimichael K., Alexopoulou E., Kelekis A., Hall B., Dourakis S., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008, 31:269-280.
5. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
6. Zhai B., Sun X.Y. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013, 5:345.
7. Berasain C. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?. Gut 2013, 62:1674-1675.
8. Ezzoukhry Z., Louandre C., Trécherel E., Godin C., Chauffert B., Dupont S., et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012, 131:2961-2969.
9. Bil J., Zapala L., Nowis D., Jakobisiak M., Golab J. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett 2010, 288:57-67.
10. Yau T., Yao T.J., Chan P., Wong H., Pang R., Fan S.T., et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011, 16:1270-1279.
11. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
12. Bodley A., Liu L.F., Israel M., Seshadri R., Koseki Y., Giuliani F.C., et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989, 49:5969-5978.
13. Keizer H.G., Pinedo H.M., Schuurhuis G.J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990, 47:219-231.
14. Seong J., Keum K.C., Han K.H., Lee D.Y., Lee J.T., Chon C.Y., et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:393-397.
15. Abou Alfa G.K., Johnson P., Knox J., Lacava J., Leung T., Mori A., et al. 3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. EJC Suppl 2007, 5:259.
16. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., et al. Abraxane®, a novel Cremphor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006, 17:1263-1268.
17. Lewis A.L., Gonzalez M., Lloyd A.W., Hall B., Tang Y., Willis S.L., et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006, 17:335-342.
18. Retnakumari A.P., Hanumanthu P.L., Malarvizhi G.L., Prabhu R., Sidharthan N., Thampi M.V., et al. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. Mol Pharm 2012, 9:3062-3078.
19. Mansur H.S., Orefice R.L., Mansur A.A. Characterization of poly (vinyl alcohol)/poly (ethylene glycol) hydrogels and PVA-derived hybrids by small-angle X-ray scattering and FTIR spectroscopy. Polymer 2004, 45:7193-7202.
20. Badalassi F., Crotti P., Di Bugno C., D'Arata F., Favero L., Ramacciotti A. Efficient enantioselective synthesis of (R)-2-acetyl-2-hydroxy-5, 8-dimethoxy-1, 2, 3, 4-tetrahydronaphthalene, the key intermediate in the synthesis of anthracycline antibiotics. Tetrahedron-Asymmetry 2001, 12:3155-3161.
21. Yang X., Zhang X., Liu Z., Ma Y., Huang Y., Chen Y. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J Phys Chem C 2008, 112:17554-17558.
22. Hasson H., Warshawsky A. HPLC analysis of adriamycine as N-2, 4-dinitrophenyladriamycine. J Liq Chromatogr 1990, 13:1637-1649.
23. Legal J.M., Manfait M., Theophanides T. Applications of FTIR spectroscopy in structural studies of cells and bacteria. J Mol Struct 1991, 242:397-407.
24. Haris P.I., Severcan F. FTIR spectroscopic characterization of protein structure in aqueous and non-aqueous media. J Mol Catal B Enzym 1999, 7:207-221.
25. Hamid R., Rotshteyn Y., Rabadi L., Parikh R., Bullock P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol in Vitro 2004, 18:703-710.
26. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008, 22:1026-1034.
27. Coradini D., Pellizzaro C., Scarlata I., Zorzet S., Garrovo C., Abolafio G. A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia 2006, 20:785-792.
28. Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006, 1:1458-1461.
29. Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma. JAMA 2010, 304:2154-2160.
30. Villanueva A., Llovet J.M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 2012, 18:1824-1826.
31. Iyer A.K., Singh A., Ganta S., Amiji M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013, 65:1784-1802.
32. Parveen S., Misra R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8:147-166.
33. Tod M., Mir O., Bancelin N., Coriat R., Thomas-Schoemann A., Taieb F., et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 2011, 28:3199-3207.
34. Burrel M., Reig M., Forner A., Barrufet M., Lope C.R.D., Tremosini S., et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012, 56:1330-1335.
35. Petrelli F., Borgonovo K., Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother 2010, 11:1413-1432.
36. Malarvizhi G.L., Chandran P., Retnakumari A.P., Ramachandran R., Gupta N., Nair S., et al. A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing. Nanomedicine 2014, 10:579-587.
37. Chandran P., Gupta N., Retnakumari A.P., Malarvizhi G.L., Keechilat P., Nair S., et al. Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine. Nanomedicine 2013, 9:1317-1327.
38. Chandran P., Kavalakatt A., Malarvizhi G.L., Vasanthakumari D.R.V.N., Retnakumari A.P., Sidharthan N., et al. Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. Nanomedicine 2013, [Article in press].
39. Ibuki Y., Toyooka T. Nanoparticle uptake measured by flow cytometry. Nanotoxicity: methods in molecular biology 2012, volume 926:157-166. Humana Press:Springer protocol. 1st ed. J. Reineke (Ed.).
40. Zucker R.M., Massaro E.J., Sanders K.M., Degn L.L., Boyes W.K. Detection of TiO2 nanoparticles in cells by flow cytometry. Cytometry A 2010, 77:677-685.
41. Lee J., Lilly G.D., Doty R.C., Podsiadlo P., Kotov N.A. In vitro toxicity testing of nanoparticles in 3D cell culture. Small 2009, 5:1213-1221.
42. Dvir-Ginzberg M., Gamlieli-Bonshtein I., Agbaria R., Cohen S. Liver tissue engineering within alginate scaffolds: effects of cell-seeding density on hepatocyte viability, morphology, and function. Tissue Eng 2003, 9:757-766.
43. Li C.L., Tian T.A.O., Nan K.J., Zhao N.A., Guo Y.H., Cui J.I.E., et al. Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. Oncol Rep 2008, 20:1465-1471.
44. Lee J., Cuddihy M.J., Cater G.M., Kotov N.A. Engineering liver tissue spheroids with inverted colloidal crystal scaffolds. Biomaterials 2009, 30:4687-4694.
45. Franko A.J., Sutherland R.M. Oxygen diffusion distance and development of necrosis in multicell spheroids. Radiat Res 1979, 79:439-453.
46. Curcio E., Salerno S., Barbieri G., De Bartolo L., Drioli E., Bader A. Mass transfer and metabolic reactions in hepatocyte spheroids cultured in rotating wall gas-permeable membrane system. Biomaterials 2007, 28:5487-5497.